Morgan Stanley
CYCN icon

Morgan Stanley’s Cyclerion Therapeutics CYCN Stock Holding History

Morgan Stanley’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 8256
2025
Q4 		$2 Sell
1
-648
-100% -$1.16K ﹤0.01% 8173
2025
Q3 		$1.49K Hold
649
– – ﹤0.01% 7352
2025
Q2 		$1.89K Hold
649
– – ﹤0.01% 7237
2025
Q1 		$1.62K Hold
649
– – ﹤0.01% 7214
2024
Q4 		$2.09K Hold
649
– – ﹤0.01% 7190
2024
Q3 		$1.68K Hold
649
– – ﹤0.01% 7163
2024
Q2 		$1.49K Hold
649
– – ﹤0.01% 7104
2024
Q1 		$2.08K Sell
649
-747
-54% -$2.39K ﹤0.01% 7060
2023
Q4 		$4.68K Buy
1,396
+573
+70% +$1.66K ﹤0.01% 7016
2023
Q3 		$2.82K Hold
823
– – ﹤0.01% 7051
2023
Q2 		$3.39K Buy
823
+221
+37% +$1.15K ﹤0.01% 7072
2023
Q1 		$5.22K Buy
602
+438
+267% +$5.53K ﹤0.01% 7038
2022
Q4 		$2.16K Sell
164
-6
-4% -$71 ﹤0.01% 7353
2022
Q3 		$3K Sell
170
-93
-35% -$1.6K ﹤0.01% 7374
2022
Q2 		$3K Sell
263
-1,696
-87% -$24.3K ﹤0.01% 7503
2022
Q1 		$43K Sell
1,959
-1,684
-46% -$40.6K ﹤0.01% 6779
2021
Q4 		$125K Sell
3,643
-82
-2% -$3.87K ﹤0.01% 6306
2021
Q3 		$229K Buy
3,725
+217
+6% +$14.2K ﹤0.01% 5926
2021
Q2 		$274K Buy
3,508
+1,619
+86% +$101K ﹤0.01% 5855
2021
Q1 		$105K Sell
1,889
-18,769
-91% -$1.41M ﹤0.01% 5977
2020
Q4 		$1.26M Buy
20,658
+17,540
+563% +$1.2M ﹤0.01% 4516
2020
Q3 		$379K Buy
3,118
+2,714
+672% +$310K ﹤0.01% 4777
2020
Q2 		$48K Buy
404
+265
+191% +$22.2K ﹤0.01% 5683
2020
Q1 		$7K Sell
139
-1,520
-92% -$108K ﹤0.01% 6102
2019
Q4 		$89K Buy
1,659
+1,160
+232% +$108K ﹤0.01% 5692
2019
Q3 		$121K Buy
499
+385
+338% +$83.2K ﹤0.01% 5368
2019
Q2 		$25K Buy
+114
New +$32.3K ﹤0.01% 5857

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's CYCN Position: Q1 2026 in Review

Morgan Stanley held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8256.

Morgan Stanley first reported a position in CYCN in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.26M in Q4 2020. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Morgan Stanley held 1 share of Cyclerion Therapeutics worth $2 as of Q1 2026.
  • Morgan Stanley left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8256 holding.
  • Morgan Stanley first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Cyclerion Therapeutics position peaked at $1.26M in Q4 2020.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.